315 related articles for article (PubMed ID: 11581420)
1. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
Skiadopoulos MH; Surman SR; Riggs JM; Collins PL; Murphy BR
J Virol; 2001 Nov; 75(21):10498-504. PubMed ID: 11581420
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
[TBL] [Abstract][Full Text] [Related]
3. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
4. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
Durbin AP; Skiadopoulos MH; McAuliffe JM; Riggs JM; Surman SR; Collins PL; Murphy BR
J Virol; 2000 Aug; 74(15):6821-31. PubMed ID: 10888621
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
[TBL] [Abstract][Full Text] [Related]
6. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Skiadopoulos MH; Surman SR; Riggs JM; Orvell C; Collins PL; Murphy BR
Virology; 2002 May; 297(1):136-52. PubMed ID: 12083844
[TBL] [Abstract][Full Text] [Related]
8. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.
Skiadopoulos MH; Schmidt AC; Riggs JM; Surman SR; Elkins WR; St Claire M; Collins PL; Murphy BR
J Virol; 2003 Jan; 77(2):1141-8. PubMed ID: 12502830
[TBL] [Abstract][Full Text] [Related]
9. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.
Bailly JE; McAuliffe JM; Durbin AP; Elkins WR; Collins PL; Murphy BR
J Virol; 2000 Apr; 74(7):3188-95. PubMed ID: 10708435
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
[TBL] [Abstract][Full Text] [Related]
11. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
Skiadopoulos MH; Tatem JM; Surman SR; Mitcho Y; Wu SL; Elkins WR; Murphy BR
Vaccine; 2002 Mar; 20(13-14):1846-52. PubMed ID: 11906774
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody.
Zhu Yd; Rota P; Wyatt L; Tamin A; Rozenblatt S; Lerche N; Moss B; Bellini W; McChesney M
Virology; 2000 Oct; 276(1):202-13. PubMed ID: 11022008
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates.
Durbin AP; McAuliffe JM; Collins PL; Murphy BR
Virology; 1999 Sep; 261(2):319-30. PubMed ID: 10497117
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.
Karron RA; Thumar B; Schappell E; Surman S; Murphy BR; Collins PL; Schmidt AC
Vaccine; 2012 Jun; 30(26):3975-81. PubMed ID: 22178099
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
[TBL] [Abstract][Full Text] [Related]
16. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
Liu X; Liang B; Liu X; Amaro-Carambot E; Surman S; Kwong PD; Graham BS; Collins PL; Munir S
PLoS One; 2020; 15(2):e0228572. PubMed ID: 32045432
[TBL] [Abstract][Full Text] [Related]
17. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
[TBL] [Abstract][Full Text] [Related]
18. Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants.
Lee MS; Mendelman PM; Sangli C; Cho I; Mathie SL; August MJ
J Infect Dis; 2001 Apr; 183(8):1281-4. PubMed ID: 11262213
[TBL] [Abstract][Full Text] [Related]
19. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
20. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Bukreyev A; Huang Z; Yang L; Elankumaran S; St Claire M; Murphy BR; Samal SK; Collins PL
J Virol; 2005 Nov; 79(21):13275-84. PubMed ID: 16227250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
